Comparison of the immunogenicity of ChAdOx1 nCoV‐19 vaccine against the wild‐type and delta variants in kidney transplant recipients and healthy volunteers

摘要

Little is known about immunogenicity after ChAdOx1 nCov‐19 vaccination after transplantation. We assessed the vaccine response by antibody testing, surrogate neutralization test (sVNT) against wild‐type (WT) and delta variant (DT), and T cell assay in 83?kidney transplant recipients (KTRs) and 52?healthy volunteers (HVs). For KTRs, a positive anti‐RBD antibody was seen in 2.8 after one dose and 15.7 after two doses of the vaccine. After two doses, the positivity rate by sVNT was equal (4.9 each, for WT and DT) and was 13.4 by T cell response. Post two doses, KTRs had significantly lower geometric mean titer than HVs (1.93 95 CI: 1.39–2.69 vs. 248.3 95 CI: 203.7–302.6 BAU/ml, respectively, p?3?mg of tacrolimus significantly associated with negative seroconversion RR?=?0.38 (95 CI, 0.17–0.85, p?=?.018) and RR?=?0.16 (95 CI, 0.37–0.73, p?=?.018), respectively. The vaccine was safe and well‐tolerated but the immune response after the two doses of ChAdOx1 nCov‐19 vaccine in KTRs was very low.